Detalles de la búsqueda
1.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol
; 19(3): 310-322, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29449192
2.
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Breast Cancer Res
; 20(1): 109, 2018 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30185228
3.
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.
Br J Cancer
; 118(6): 777-784, 2018 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438370
4.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 17(9): 1248-60, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27480103
5.
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Drug Metab Dispos
; 44(1): 28-39, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26451002
6.
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
Invest New Drugs
; 31(2): 363-9, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22547164
7.
Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.
Mol Pharm
; 10(11): 4046-54, 2013 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24010577
8.
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
Clin Cancer Res
; 26(1): 46-53, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732523
9.
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.
Clin Cancer Res
; 25(11): 3239-3246, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30824584
10.
High throughput protein production and crystallization at NYSGXRC.
Methods Mol Biol
; 426: 561-75, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18542890
11.
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
Pigment Cell Melanoma Res
; 31(4): 516-522, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29156488
12.
Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study.
JCO Precis Oncol
; 2: 1-18, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35135126
13.
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
Clin Cancer Res
; 23(17): 5238-5245, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28536307
14.
MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Clin Cancer Res
; 20(24): 6324-35, 2014 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25326231
15.
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
Mol Cancer Ther
; 8(12): 3181-90, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19934279
16.
Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.
J Biol Chem
; 280(2): 1346-53, 2005 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-15528182
Resultados
1 -
16
de 16
1
Próxima >
>>